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Abstract
Background: Bladder cancer is a very heterogeneous disease as regards natural history. Environmental exposures,
constitutional genetic and/or epigenetic background may affect not only the likelihood of bladder tumor occurrence,
but also the histologic type of cancer and its outcome. Currently, only a few data are available to study the prognostic
role of genetic and environmental factors. Likewise, data on the economic burden of bladder cancer and the
longitudinal impact of the disease and the treatments on patient quality of life are scarce.
Methods: COBLAnCE is a large French-based clinical cohort study on bladder cancer. Newly diagnosed patients are
enrolled prospectively in 12 public hospitals and 5 private for profits hospitals. The target sample size is 2,000 patients.
All patients are to be followed for 6 years. Information on patient characteristics and lifestyle is collected during a face-
to-face interview at enrollment. Clinical information on disease presentation, diagnosis, and treatment is extracted from
medical records for the primary tumor and for all subsequent local and distant recurrences. Quality of life and resource
use is collected at recruitment and during follow-up. In parallel, 4 types of biological samples (blood, tumor tissue,
urine and nail) are collected, at baseline and during follow-up. DNA, RNA and PBMLs are extracted from blood samples,
DNA and RNA from stabilized urine, proteins from frozen urine, DNA, RNA and proteins from frozen tumor tissues, and
DNA and RNA from formalin-fixed paraffin-embedded tumor tissues. All derived products are stored at −80 °C or in
liquid nitrogen. Main endpoints are gene-environment interactions, molecular classification, biomarker discovery,
therapeutic innovation, treatment patterns, healthcare resource use, bladder cancer outcomes and quality of life.
Discussion: The COBLAnCE cohort will provide considerable insight into the biology of bladder cancer and the
mechanisms through which genetic and environmental factors may influence the prognosis. It may allow the
discovery of emerging biomarkers. Finally, economic data will be useful for future cost-effectiveness studies of
immunotherapy drugs or other therapeutics in bladder cancer.
Keywords: Bladder cancer, Cohort study, Biobanks, Gene-environment interactions, Molecular classification, Biomarkers,
Healthcare resource use, Quality of life, Outcomes
Background
In Europe, bladder cancer is the second most common
malignancy of the urinary tract, after prostate cancer, in
men [1]. In 2012, the estimated incidence of bladder
cancer was 151 300, of which 118 400 were diagnosed in
men and 32 900 were diagnosed in women [1]. In men,
bladder cancer was the fourth most commonly diagnosed
cancer and accounted for 4.0% of all cancer-related deaths
[1]. Approximately ¾ of bladder cancers occur at the age
of 65 years or more [1]. Main risk factors include tobacco
smoking and some occupational exposures [2]. Genetic
factors could also contribute to bladder cancer develop-
ment. The risk of bladder cancer is 2-fold higher in first-
degree relatives of bladder cancer patients. Common
polymorphisms in two carcinogen detoxification genes, N-
acetyltransferase 2 (NAT2) and glutathione-S-transferase
M1 (GSTM1), have been consistently associated with blad-
der cancer risk and several studies suggested that the
NAT2 slow acetylation genotype interacts with smoking
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intensity [3]. However, additional large investigations of
bladder cancer risk, NAT2 genetic variation and com-
prehensive assessment of smoking habits, notably flue- or
air-cured tobacco, are still needed to further assess this
interaction. Recently, genome-wide association studies
have identified around ten common susceptibility loci as-
sociated with bladder cancer risk [4, 5]. In contrast, little
is known on the relationships between genetic
markers, behavioral and environmental factors, and
bladder cancer outcome.
Bladder cancer is a very heterogeneous disease with a
variable natural history. Ninety to 95% of all bladder
cancers are urothelial cell carcinomas. Urothelial car-
cinomas are classified into two broad categories: non-
muscle-invasive bladder cancers (NMIBC) which are
restricted to the urothelial cell layers (stage Ta or Tis)
or only penetrate the lamina propria (stage T1), and
muscle-invasive bladder tumors (MIBC). About 80% of all
newly diagnosed bladder carcinomas present as NMIBC
and 20% as MIBC. The disease is characterized by a wide
range of outcomes. At one end of the spectrum, low-grade
NMIBC rarely progress to aggressive or metastatic tumors
but as many as half will recur [6]. At the other extreme,
high-grade NMIBC have a high malignant potential associ-
ated with significant progression (20% of patients develop
a MIBC bladder cancer), and 50% of MIBC are associated
with cancer death [7].
In the United States, several studies have shown that
bladder cancer represents an economic burden for pa-
tients and society [8]. However, few economic data based
on patient level data are available in Europe especially
regarding the cost-effectiveness of many recent and
costly interventions. Given the major differences be-
tween healthcare systems, it is important to assess the
economic burden of bladder cancer in different juris-
dictions [9]. Similarly, good quality data on the longitu-
dinal impact of both the disease and the treatments on
the patient quality of life (QoL) are scarce [10]. In par-
ticular, there is limited QoL data in metastatic patients
and in non-muscle invasive tumors where the rhythm
of endoscopic surveillance could be adapted according
to the repercussions on the various dimensions of QoL
(functional dimension and anxiety).
Overall, environmental exposures, constitutional gen-
etic and/or epigenetic background may affect not only
the likelihood of bladder tumor occurrence but also the
type of cancer which will occur. More specifically, they
may determine the oncogenesis pathway followed by
bladder tumorigenesis. Today, there are only very few
data available to address these issues, probably because
of a lack of samples of patients well enough clinically,
epidemiologically and biologically characterized. There is
therefore a need for well designed, adequately-powered
cohort study to investigate gene-environment interactions,
pathological and molecular classification, biomarker
discovery, therapeutic innovation, treatment patterns,




COBLAnCE (a COhort to study BLAdder CancEr) is a
national, non-interventional, prospective cohort of newly
diagnosed bladder cancer patients. Twelve French public
hospitals (including 9 university institutions) and 5 pri-
vate for profits hospitals participate in the enrollment.
The study protocol has been approved by the French
regulatory authorities (data protection authority Com-
mission Nationale de l’Informatique et des Libertés
(CNIL) N° DR-2012-441 and biological collections au-
thority N° DC-2011-1486) and a French ethics committee
(Comité de Protection des Personnes Ile de France VII
(N° CO-12-001). COBLAnCE adapted the Integrated
Study on Bladder Cancer (ISBlaC) tools that were kindly
provided by Dr Malats (National Cancer Research Centre
(CNIO), Madrid, Spain). Each patient enrolled in the study
provides a written informed consent. Enrollment started
in December 2012.
The study has been designated:
1) To evaluate the association between constitutional
DNA polymorphisms, environmental parameters,
molecular bladder cancer subtypes and outcomes.
The inclusion of features of both the tumor and the
host will facilitate the discovery of tumorigenesis
mechanisms, drugable targets and diagnostic and
prognostic biomarkers.
We will comprehensively assess interactions between
smoking habits, notably flue- or air-cured tobacco,
and genetic variants on bladder cancer risk. Such
analyses are possible in France where the great ma-
jority of cigarette smokers were air-cured tobacco
users before the 1970’s. Changes in smoking habits
are recorded during the follow-up period and will
allow evaluating the impact of continuing smoking
after bladder cancer diagnosis on recurrence and
survival. More generally, this study will make
possible the assessment of the impact of various
environmental and occupational exposures on
bladder cancer presentation and prognosis, and
whether these relationships are modulated by
genetic markers.
2) To improve the molecular subtyping of bladder
cancer on a large series of tumors collected
prospectively integrating transcriptome (both
coding and non-coding RNA), proteome, genomic
alterations and epigenetic modifications. The
identification of homogeneous classes of bladder
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cancers is a fundamental step towards tailored
treatments and more reliable predictive markers
of treatment response.
Beyond the NMIBC / MIBC dichotomy, the huge
heterogeneity of bladder cancer requires large
number of samples and high throughput technologies
to unravel reliable molecular subtypes. The specific
associations between molecular subtype occurrence
and genetic and/or environmental background will
be explored.
3) To provide insight into the tumor progression
comprehension and to help to identify biomarkers
by the sequential sampling of recurrent tumors and
urine from individual patients during follow-up.
Molecular comparison of primary tumor with
samples at recurrence and/or progression will allow
phylogenetic analysis, phenotypic stability and tumor
heterogeneity assessment. The specifically molecular
changes associated with clinical steps will be tested as
potential driving events and/or prognosis biomarkers.
4) To describe treatment patterns and to assess QoL
and direct and indirect costs attributable to bladder
cancer from the payer perspective with a long-term
follow-up.
These data will help decisions by all stakeholders
and policymakers. It will be of paramount
importance in the context of implementation of
new diagnostic or therapeutic modalities.
Patient population
Patients, regardless of age and sex, are eligible to partici-
pate in the study if they are diagnosed in one of the par-
ticipating centers with no history of bladder cancer, with
at least one signal (symptoms, imaging results) that is sus-
pected to be of bladder cancer origin and are to undergo
transurethral resection or cystectomy in order to obtain a
final histologic diagnosis. All histological types are eligible.
Follow-up schedule
All patients will be followed over a 6-year period as most
first recurrence and cases of progression occur during
this time scale. Treatment follow-up is based on the
European Association of Urology recommendations, i.e.
routine visits at 3 months, 6 months, 12 months for high
grade tumors including cytology and cystoscopy, and
annually thereafter [11]. Information on health status is
recorded at each follow-up visit.
Data collection and data management
Information on patient characteristics and lifestyle is
collected during a face-to-face interview at enrollment.
Interviews are conducted by trained interviewers at
each of the 17 recruiting centers and take approximately
50 min. Clinical information on disease presentation,
diagnosis, and treatment is extracted from patient med-
ical records for the primary tumor and for all subse-
quent local and distant recurrences. Quality of life is
collected using self-administered questionnaires at re-
cruitment and at 6 months, 12 months, and then annu-
ally if no local recurrence occur, and at 3 months,
6 months 12 months and then annually in case of local
recurrence. Two types of questionnaires are used: the
EuroQol EQ-5D questionnaire and the EORTC QLQ-
C30 core questionnaire as well as additional modules,
which have been developed to measure QoL in patients
with bladder cancer (BLS 24 and BLM 30). Finally, re-
source use is collected during the different steps of the
management of bladder cancer distinguishing between
non-muscle-invasive and muscle-invasive tumors: diag-
nosis, surgery, adjuvant treatments, surveillance, and
treatment of local and distant recurrences. Main data
collected are provided in Table 1.
Structured and secured electronic Case Report Forms
(eCRFs) have been developed for the study. Subjects are
assigned a study identification number which identifies
their data. Names are removed from the data and the
correspondence between the name and the identification
number is kept in centers. eCRFs are entered online at
each participating center into a central database
(‘MACRO’) specifically designed to store all collected
data. The database comprises automatic range and logic
checks to reduce data entry errors. A data manager
identifies missing or inconsistent data and returns
queries to centers.
Sample collection
For each patient, four types of samples (blood, tumor
tissue, urine and nail) are collected, at baseline and/or
during follow-up, and delivered to three Biological
Resources Centers (BRC) (NF S96-900 certification
obtained for two BCR and being requested for one
BRC) for processing and storage in cryoconservators
or freezers which are alarmed and continuously moni-
tored (Table 2).
Sampling kits including all tubes/containers required
for the study and packaging for the shipment are prepared
by the BRC of the Jean Dausset Foundation – Human
Polymorphism Study Center (HPSC-BRC) in Paris and
sent to participating centers. All contents are pre-labeled
with a unique bar code to provide full traceability from
the patient inclusion.
Blood samples
Blood samples are collected prior to surgery in three
tubes (10 ml in one EDTA-containing tube for DNA ex-
traction and isolation of plasma, 6 ml in one citrate-
containing tube for isolation of lymphocytes, and 2.5 ml
in one PAXgene tube for RNA extraction). The same
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day samples are shipped by centers to the HPSC-BRC
where they are processed at reception (24 to 72 h after
blood sampling). Viable lymphocytes are isolated using
‘UNI-SEP Lymphocyte Separation’ tubes (Eurobio) and
stored in liquid nitrogen. Aliquots of plasma and buffy-
coats isolated from EDTA blood are stored at −80 °C.
DNA is extracted from buffy-coats using a salting out
protocol on the Autopure LS (Qiagen). DNA concentra-
tions are measured using ‘PicoGreen dsDNA reagent’
(Life Technologies). DNAs are diluted sequentially using
TE10:1 to get concentrations normalized at 100 ng/μL.
Integrity of DNA is checked on agarose gel on 20% of
extracted DNAs. Gender is systematically checked on all
DNAs extracted using a PCR method [12].
RNA is extracted from PAXgene tubes using PAXgene
Blood miRNA Kit (Qiagen) on the QIAcube (Qiagen).
RNA concentration is measured on a NanoDrop 2000C
(Thermo Scientific) and quality of RNA is evaluated by
calculation of the RIN (RNA Integrity Number) on a
Bioanalyzer 2100 (Agilent).
Table 1 Data collection
Type of data Data collected Data Source
Epidemiology (1) Sociodemographic characteristics: age, sex, place of birth, educational level, marital status,
household income, working situation, history of residences and of occupations.
(2) Lifestyle: history of tobacco consumption, dietary habits and physical activity.
(3) Medical history and medication use: weight, height, urinary tract infection, hematuria, kidney
stones, skin or respiratory allergies, anti-hypercholesteremic and anti-inflammatory drugs, hormonal
treatment, personal and family history of cancer
Face to face interview
Disease management (1) Disease presentation: presence of symptoms (hematuria, pollakuria, dysuria, urgency,
hydronephrosis), alteration of health status
(2) Procedures before diagnostic resection: urinary cytology, urine culture, abdominal ultrasound,
urinary tract fibroscopies, imaging (scanner, MRI)
(3) Diagnosis through transurethral resection of the bladder: Hervix or Narrow-Band-Imaging (NBI)
fluorescence, number and location of resected tumors, size and aspect of the largest tumor
(4) Treatment: for NMIBC intravesical instillations and cystectomy; for MIBC: chemotherapy,
radiotherapy, for both NMIBC and MIBC: lymphadenectomy, urethrectomy, nephro-urethrectomy,
urinary diversion, blood transfusion, any hospitalization and complications.




Pathology (1) Histological type and subtype
(2) Prognosis factors : for NMIBC tumor stage, grade, CIS associated, lymphovascular invasion; for MIBC,
TNM stage, surgical margins, lymphovascular invasion, lymph node density
(3) Pathological review for all cases at initial diagnosis and recurrence
Patient medical
records
Resource use (1) All hospitalizations: dates, type of facility, service, type of care and diagnosis-related group.
(2) Outpatient and community care : Cystoscopies, Imaging (CT, MRI, ultrasound, etc.), urine cytology,






Quality of life (1) Generic measure: EuroQol EQ-5D-3 L questionnaire
(2) Generic measure: EORTC QLQ-C30 questionnaire
(3) Specific measures: urinary and bowel symptoms, impairment due to repeated treatments and
sexual functioning.
- EORTC-BLS24 questionnaire for patients treated with transurethral resection of the bladder
- EORTC-BLM30 questionnaire for those who underwent cystectomy
Self-administered
questionnaires
Table 2 Sample collection
Time of collection Sample Derived products Storage













(4) Nail Room temperature












PBMLs, peripheral blood mononuclear leukocytes; FFPE, formalin-fixed paraffin-embedded
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Tumor samples
Tumor tissue is sampled at first transurethral resection
of bladder tumor and transferred to the pathology de-
partment for diagnosis according to routine procedures,
including formalin fixation and embedding in paraffin
(FFPE blocks). If the tumor is large enough (diameter >
10 mm), a sample is snap-frozen and stored at −80 °C in
freezers located at each center. Frozen tumor samples
are shipped every three months on dry ice to the bio-
logical resources platform of the Curie Institute in Paris
for DNA, RNA and proteins extraction, aliquoting and
storage at −80 °C. A representative FFPE block and slides
used for diagnosis are sent at room temperature to the
Mondor hospital’s biological resources platform for patho-
logical review, DNA and RNA extraction, and Tissue Mi-
cro Arrays construction for future immunohistochemical
and/or in situ hybridization analysis.
Cryosections are performed from frozen samples to
check for tumor cell content by an uropathologist. Follow-
ing the uropathologist report, macrodissections is per-
formed on the frozen samples using a scalpel to take
fragments enriched in tumor cells and the percentages of
tumor cells of the microdissected fragments are recorded.
When the samples are of sufficient size, a fragment of
around 120 mg is taken. The remaining of the sample is
stored at −80 °C. To extract RNA, DNA and protein from
the same part of the tumor, each fragment is frozen in li-
quid nitrogen and is ground in a mortar. If the fragment is
of sufficient size (above 45 mg), the powder is divided in
three equal parts, for RNA and DNA extractions and for
protein extract. If the quantity of material is limiting,
DNA, then RNA are prioritized. Between 20 and 45 mg,
the powder will be divided in two parts for RNA and DNA
extractions. Below 20 mg, only DNA will be extracted.
DNA is extracted following a phenol-chloroform proced-
ure and quantified using a NanoDrop spectrophotometer
and a Qubit fluorometer. The quality of the DNA is verified
by electrophoresis. RNA is extracted using the TissueLyzer
(Qiagen) and the Qiagen miRNeasy kit. RNA is quantified
with a Nanodrop spectrophotometer. The RIN (RNA
integrity number) is measured on an Agilent 2100 bioana-
lyzer. For protein, the powder is dissolved in a Laemmli
buffer using the TissueLyzer (Qiagen) and the proteins are
quantified with the Pierce BCA kit. To spare materials,
amplifications of RNA and DNA are performed as some
analyses can be done on amplified materials. To obtain
DNA and RNA from all tumors of the COBLAnCE cohort,
DNA and RNA are being extracted from paraffin materials.
For FFPE samples, slides are prepared from each block.
New HES coloration, as control, is realized, the slide is
scanned and archived. A GATA3/CK5/6 double-staining
immunohistochemistry is performed to classify the tumor
at molecular level [13, 14] and guide Tissue Micro Arrays
and DNA/RNA extraction performed on selected zones.
DNA and RNA (Recover All) are extracted using
Maxwel automate and specific FFPE kits (Promega).
DNA and RNA concentrations are quantified using
Qubit technology. Samples are stored at −80 °C.
In case of recurrence, both fresh and paraffin-embedded
tumor tissue samples are collected and processed as
previously described.
Urine samples
A urine sample is collected prior to surgery. 50 ml of
these urine samples is stored at room temperature in
Norgen® tubes (Thorold, Canada) for nucleic acid extrac-
tion and the surplus is immediately frozen at −80 °C in
Falcon tubes for further protein extraction.
Norgen® and frozen urine samples are shipped every
three months at room temperature and on dry ice re-
spectively to the Platform of Biological Resources - Henri
Mondor Hospital to be processed.
DNA and RNA are extracted with the automated
Maxwell 16 Instrument (Promega, Lyon, France), using
the Maxwell LEV DNA Blood Kit and LEV RNA tissue
Kit respectively. 25 ml of Norgen® urine is used for each
DNA or RNA extraction on pellet after centrifugation.
For DNA extraction, each sample is centrifuged at
2000 g for 10 min. Purified DNA and RNA samples are
eluted in 50 μL nuclease-free water and stored at −80 °C
in the Plateform of Biological Resources (Henri Mondor
Hospital) until processed. Nucleic acids concentration is
determined using NanoDrop 2000C (Thermo Scientific).
To extract urine protein, thawed urine is centrifuged at
1300 xg for 10 min at room temperature. Then, protein is
isolated from both the supernatant and the obtained pellet
separately. Proteins from the pellet are extracted by 200 μl
of T-PER reagent (Tissue Protein Extraction Reagent,
Thermo scientific), containing protease and phosphatase
inhibitors. Proteins from the initial urine supernatant are
precipitated by trichloracetic acid (TCA 30%, Sigma-Al-
drich) to a final concentration of 6%, and the pellet is
washed twice with ice-cold acetone (Sigma-Aldrich) and
air-dried. Proteins are stored at −80 °C in the Platform of
Biological Resources (Henri Mondor Hospital).
Protein concentration is assessed with Pierce BCA
protein assay kit (Thermo Scientific).
An additional urine sample is collected at the 12 months
follow-up visit for patients not treated with radical cystec-
tomy and processed as previously described.
Toenail clippings
Toenail clippings are collected at the time the baseline
questionnaire is completed and blood samples are
collected. They are delivered to HPSC-BRC in a sealed
envelope along with blood samples, and then mailed to
the Mondor hospital’s biological resources platform
every three months for storage at ambient temperature.
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Power considerations and data analysis
We planned to enroll 2,000 patients. We assumed a
recruitment period of 5 years (50% of the patients
recruited the 3 first years and 50% the 2 last years), a
loss to follow-up rate of 10% during the 3 first years, 5%
during the 2 following years, and 5% thereafter, and a
progression rate of 40% at 4 years and 50% at 5 years.
Based on the literature data, 30% of bladder cancer pa-
tients present with a MIBC at the time of diagnosis. We
therefore expect 600 patients with MIBC to be included;
the progression free survival is the primary endpoint of
interest for these patients. The study will be sufficiently
powered (bilateral test, α = 0.05, 1-β ≥ 80%) to detect a
hazard ratio ≥ 2 considering a prevalence of marker pro-
gression between 10% and 20%, or a hazard ratio ≥ 1.5
for a prevalence marker between 30% and 50%.
Data analyses will be performed to complement specific
objectives outlined above. Various parameters which are
planned to be assessed have been summarized in Table 1.
All analyses will be carried out using SAS version 9.1 (SAS
Institute, Cary, NC, USA) and STATA (Version 13, Stata
Corporation, Austin, Texas).
Discussion
To date (March 2016), 13 centers are actively involved in
subject recruitment and 1020 patients have already been
enrolled in the study. Recruitment is expected to end in
the first semester of 2017. This ambitious project will
allow having one of the biggest cohorts of incident bladder
tumors with a longest follow-up (minimum 6 years).
This study will provide us with considerable insight into
the biology of bladder cancer and the mechanisms through
which various factors may alter the prognosis. It should fa-
cilitate the identification and the cost-effectiveness of emer-
ging biomarkers and targeted therapies in bladder cancer.
The multidisciplinary approach of this study will allow
communication with other researchers and departments
to share ideas and foster collaborations. In fact epidemi-
ologists, clinicians, biologists, pathologists, health econo-
mists, researchers coming from various French institutions
joined together to build this cohort. In addition, the inter-
action with many health centers will support the transla-
tion of our research findings into clinical practice.
During the follow-up period, new experimental drugs
for bladder cancer treatment may be recorded. For the
purpose of these registrations, data prospectively collected
in COBLAnCE will be useful to describe the natural
history of bladder tumor evolution in France.
In summary, the establishment of this cohort study,
along with the wealth of epidemiological, clinicipatholo-
gical, economical and biological evidence to be collected,
will lead to a much needed understanding of bladder can-
cer and provide evidence to guide health professionals in
the management and care of patients with this disease.
Despite the large size of this prospective cohort, larger
studies are necessary for specific analyses in subgroups
of patients, i.e. within stage of disease, or within groups
of patients with the same treatment. Therefore, we
intend to establish close collaborations with other on-
going prospective studies on bladder cancer in order to
combine the datasets and accordingly to increase the
statistical power.
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